James J Ferguson

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions
    J J Ferguson
    St Luke s, Episcopal Hospital, Cardiology Research, Houston, TX 77030, USA
    Drugs 58:965-82. 1999
  2. ncbi request reprint The role of oral antiplatelet agents in atherothrombotic disease
    James J Ferguson
    Texas Heart Institute, St Luke s Episcopal Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiovasc Drugs 6:149-57. 2006
  3. ncbi request reprint Of Swiss alchemists and road hazards
    James J Ferguson
    Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston, Texas Heart Institute, Houston, Texas, USA
    J Invasive Cardiol 19:437-8. 2007
  4. ncbi request reprint Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study
    James J Ferguson
    Cardiology Research 1 191, St Luke s Episcopal Hospital, Houston, Tex 77225, USA
    Am Heart J 146:628-34. 2003
  5. ncbi request reprint Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI
    J J Ferguson
    Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston 77030, USA
    Minerva Cardioangiol 55:529-56. 2007
  6. ncbi request reprint Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes
    James Ferguson
    Cardiology Research, M C 1 19, St Luke s Episcopal Hospital, P O Box 20269, Houston, TX 77225, USA
    J Invasive Cardiol 16:136-44. 2004
  7. ncbi request reprint If there's smoke, is there fire?
    James J Ferguson
    Texas Heart Institute, St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, TX 77225 0345, USA
    Circulation 109:1442-4. 2004
  8. ncbi request reprint Low molecular weight heparins and glycoprotein IIb/IIIa antagonists
    James J Ferguson
    St Luke s Episcopal Hospital, Texas Heart Institute, University of Texas Health Science Center at Houston, Baylor College of Medicine, Houston, Texas, USA
    J Interv Cardiol 15:147-54. 2002
  9. ncbi request reprint The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry
    J J Ferguson
    Texas Heart Institute, Houston, Texas 77030, USA
    J Am Coll Cardiol 38:1456-62. 2001
  10. ncbi request reprint Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin
    J J Ferguson
    Cardiology Research, St Luke s Episcopal Hospital, Houston, TX 77225, USA
    J Invasive Cardiol 12:E10-3;discussion E25-8. 2000

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions
    J J Ferguson
    St Luke s, Episcopal Hospital, Cardiology Research, Houston, TX 77030, USA
    Drugs 58:965-82. 1999
    ..Ongoing and future studies will further refine the role of GP IIb/IIIa antagonists, explore new applications, and further test their safety and cost effectiveness in the short and long term...
  2. ncbi request reprint The role of oral antiplatelet agents in atherothrombotic disease
    James J Ferguson
    Texas Heart Institute, St Luke s Episcopal Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiovasc Drugs 6:149-57. 2006
    ..Recent data suggest that clopidogrel may have a significant role, with or without fibrinolytic therapy, in the immediate management of ST-segment elevation ACS...
  3. ncbi request reprint Of Swiss alchemists and road hazards
    James J Ferguson
    Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston, Texas Heart Institute, Houston, Texas, USA
    J Invasive Cardiol 19:437-8. 2007
  4. ncbi request reprint Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study
    James J Ferguson
    Cardiology Research 1 191, St Luke s Episcopal Hospital, Houston, Tex 77225, USA
    Am Heart J 146:628-34. 2003
    ....
  5. ncbi request reprint Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI
    J J Ferguson
    Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston 77030, USA
    Minerva Cardioangiol 55:529-56. 2007
    ....
  6. ncbi request reprint Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes
    James Ferguson
    Cardiology Research, M C 1 19, St Luke s Episcopal Hospital, P O Box 20269, Houston, TX 77225, USA
    J Invasive Cardiol 16:136-44. 2004
    ..The combined use of a LMWH and a GP IIb/IIIa antagonist should now be viewed as safe and effective in the management of acute coronary syndromes. Definitive efficacy-powered superiority data will be available shortly...
  7. ncbi request reprint If there's smoke, is there fire?
    James J Ferguson
    Texas Heart Institute, St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, TX 77225 0345, USA
    Circulation 109:1442-4. 2004
  8. ncbi request reprint Low molecular weight heparins and glycoprotein IIb/IIIa antagonists
    James J Ferguson
    St Luke s Episcopal Hospital, Texas Heart Institute, University of Texas Health Science Center at Houston, Baylor College of Medicine, Houston, Texas, USA
    J Interv Cardiol 15:147-54. 2002
    ..As the standard of care moves forward, we will see increasing use of LMWHs, with and without GP IIb/IIIa antagonists in conservatively and invasively managed patients...
  9. ncbi request reprint The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry
    J J Ferguson
    Texas Heart Institute, Houston, Texas 77030, USA
    J Am Coll Cardiol 38:1456-62. 2001
    ....
  10. ncbi request reprint Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin
    J J Ferguson
    Cardiology Research, St Luke s Episcopal Hospital, Houston, TX 77225, USA
    J Invasive Cardiol 12:E10-3;discussion E25-8. 2000
    ..NICE 3 builds on the previous experiences of NICE 1 and NICE 4 with LMWH in the cath lab (with or without GP IIb/IIIa antagonists) to more aggressively extend the use of LMWHs into the medical management of ACS patients...
  11. ncbi request reprint Angiography and interventional cardiology
    James J Ferguson
    Cardiology Research, St Luke s Episcopal Hospital, Houston, Texas 77030, USA
    J Am Coll Cardiol 44:13A-15A. 2004
  12. pmc Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention
    Jose G Diez
    Department of Internal Medicine, Texas Heart Institute at St Luke s Episcopal Hospital, USA
    Tex Heart Inst J 36:98-103. 2009
    ..Therefore, we believe that intravenous enoxaparin is a safe alternative to unfractionated heparin in both settings...
  13. ncbi request reprint Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade
    Glenn N Levine
    Baylor College of Medicine and the Houston VA Medical Center, Houston, Texas 77030, USA
    Catheter Cardiovasc Interv 66:149-57. 2005
    ..The percentages of patients undergoing invasive and revascularization procedures were consistently higher in the U.S. cohorts of study subjects when compared to non-U.S. cohorts of study subjects...
  14. ncbi request reprint Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarction
    James J Ferguson
    Cardiology Research, St Luke s Episcopal Hospital, Texas Heart Institute, Houston 77030, USA
    Clin Cardiol 25:I16-22. 2002
    ..At present, however, practitioners need to consider individually how comfortable they are with the available data...
  15. ncbi request reprint Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendations
    Glenn N Levine
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Catheter Cardiovasc Interv 60:185-93. 2003
  16. pmc Low-molecular-weight heparins in the cardiac catheterization laboratory
    Rajan A Kadakia
    Department of Cardiology Research, Texas Heart Institute, St Luke s Episcopal Hospital, Houston, Texas 77225 0269, USA
    Tex Heart Inst J 31:72-83. 2004
    ....
  17. doi request reprint Circadian body temperature variability is an indicator of poor prognosis in cardiomyopathic hamsters
    Amany Ahmed
    Texas Heart Institute at St Luke s Episcopal Hospital, 6770Bertner Avenue, Houston, TX 77030, USA
    J Card Fail 16:268-74. 2010
    ..Our goal was to use cardiomyopathic hamsters to examine the relationship between body temperature and heart failure decompensation and death...
  18. ncbi request reprint Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary intervention
    Emerson C Perin
    Department of Adult Cardiology, Texas Heart Institute St Luke s Episcopal Hospital, and Baylor College of Medicine, Houston, Tex, USA
    Am Heart J 144:693-701. 2002
    ..Postinterventional ischemic myocardial dysfunction and its sequelae are still not well understood...
  19. ncbi request reprint Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicine
    John F Canales
    Department of Cardiology Research, Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston, Texas 77225 0269, USA
    Am J Cardiovasc Drugs 8:15-25. 2008
    ....
  20. ncbi request reprint Direct stenting and placement of a distal protection device after laser angioplasty in a saphenous vein graft with severe stenosis
    Shun Kohsaka
    Department of Cardiology, Texas Heart Institute, St Luke s Episcopal Hospital, 6720 Bertner Avenue, M C 1 133, Houston, TX, USA
    J Invasive Cardiol 17:160-2. 2005
  21. ncbi request reprint Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
    Eric J Topol
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Med 113:1-6. 2002
    ..Brief intervention with this monoclonal antibody during percutaneous coronary revascularization is associated with significant improvement of long-term survival...
  22. ncbi request reprint Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Catheter Cardiovasc Interv 69:73-83. 2007
    ..Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS)...
  23. ncbi request reprint Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 152:1042-50. 2006
    ..The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding...
  24. ncbi request reprint Strategies for optimizing outcomes in the NSTE-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report
    Marc Cohen
    J Invasive Cardiol 18:617-39. 2006
    ..The addition of statins, ACE-inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease...
  25. ncbi request reprint Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:315-21. 2007
    ..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
  26. ncbi request reprint Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
    Chadwick D Miller
    Department of Emergency Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Eur Heart J 28:1079-84. 2007
    ..We compared the initial treatment and clinical outcomes of patients presenting with evolving MI (EMI) with those presenting with MI...
  27. ncbi request reprint Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus
    Dean J Kereiakes
    Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 144:615-24. 2002
    ....
  28. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
    ..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
  29. ncbi request reprint Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III
    Marc Cohen
    Cardiac Cath Lab, 2nd Floor Bridge, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, 07112, USA
    J Invasive Cardiol 19:525-38; quiz 539-40. 2007
    ..The addition of statins, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease...
  30. pmc Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 23:310-6. 2008
    ..Despite advances in pharmacologic therapy and invasive management strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), these patients still suffer substantial morbidity and mortality...
  31. doi request reprint Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy
    Derek P Chew
    Flinders Medical Centre, South Australia, Adelaide, Australia
    Am Heart J 155:239-44. 2008
    ..We explored the clinical outcomes among high-risk patients undergoing CABG and the impact of modern pharmacology...
  32. doi request reprint Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
    Fundam Clin Pharmacol 22:315-21. 2008
    ..This excess risk should be considered when choosing the optimal antiplatelet strategy for long-term treatment of patients with prior occlusive vascular events or those at high risk of developing occlusive vascular disease...
  33. doi request reprint Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
    Steve Leung
    University of Kentucky, Lexington, KY, USA
    Am Heart J 156:177-84. 2008
    ..Smoking remains a major public health issue. We investigated the incidence of smoking and outcomes in high-risk patients with acute coronary syndromes. Differences in treatment effect of antithrombin therapies were also investigated...
  34. ncbi request reprint A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
    Marc Cohen
    HEART Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 48:1346-54. 2006
    ....
  35. ncbi request reprint Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial
    James J Ferguson
    JAMA 292:45-54. 2004
    ..Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy...
  36. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  37. ncbi request reprint Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS
    Dean J Kereiakes
    The Lindner Center for Research and Education, Ohio State University, Cincinnati, USA
    J Invasive Cardiol 15:536-53. 2003
  38. ncbi request reprint Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
    John L Petersen
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:269-76. 2004
    ..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
  39. ncbi request reprint Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 149:S81-90. 2005
    ..However, the critical trials comparing enoxaparin with UFH were conducted before the widespread use of early invasive management and the availability of clopidogrel and glycoprotein IIb/IIIa receptor antagonists...
  40. ncbi request reprint High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2594-600. 2005
    ....
  41. ncbi request reprint A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 149:S91-9. 2005
    ..Contemporary guidelines from the American College of Cardiology/American Heart Association call for use of low-molecular-weight heparin or unfractionated heparin (UFH)...
  42. ncbi request reprint Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry
    Gregg W Stone
    Cardiovascular Research Foundation and Lenox Hill Hospital, 55 East 59th Street, 6th Floor, New York, NY 10022, USA
    J Am Coll Cardiol 41:1940-5. 2003
    ..We sought to examine contemporary utilization patterns and clinical outcomes in patients with acute myocardial infarction (AMI) requiring intra-aortic balloon pump (IABP) counterpulsation...
  43. pmc 2004: that was the year that was
    James J Ferguson
    Tex Heart Inst J 32:2-6. 2005
  44. ncbi request reprint Comparison of outcomes after 8 vs. 9.5 French size intra-aortic balloon counterpulsation catheters based on 9,332 patients in the prospective Benchmark registry
    Marc Cohen
    Division of Cardiology, M C P Hahnemann University, Philadelphia, Pennsylvania, USA
    Catheter Cardiovasc Interv 56:200-6. 2002
    ..The large, population-based, ongoing Benchmark registry provides a useful vehicle for outcomes research concerning the evolving practice of IABC...
  45. ncbi request reprint Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, PA, Philadelphia, USA
    Eur Heart J 24:1763-70. 2003
    ..To examine differences in patient characteristics and outcomes in 19636 patients enrolled in the USA and 3027 patients enrolled in other countries undergoing intra-aortic balloon pump (IABP) counterpulsation...
  46. doi request reprint Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict
    Derek P Chew
    Flinders Medical Centre, Adelaide, Australia
    Am Heart J 155:841-7. 2008
    ..We assessed the ability to predict need for CABG from demographics known at the time of ACS presentation, using data from SYNERGY...
  47. pmc A word from the dark side
    James J Ferguson
    Tex Heart Inst J 35:1. 2008
  48. ncbi request reprint Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 106:1243-50. 2002
    ..No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI...
  49. ncbi request reprint In-hospital mortality associated with the use of intra-aortic balloon counterpulsation
    Philip M Urban
    La Tour Hospital, Geneva, Switzerland
    Am J Cardiol 94:181-5. 2004
    ..Therefore, diagnostic evaluation and treatment decisions should be made as early as possible, and physicians should be aware of associated risk factors in making choices for patients...
  50. pmc Retroactive indexing: the apotheosis of a laboratory bulletin?
    James J Ferguson
    Tex Heart Inst J 31:205. 2004
  51. pmc The times, they ARE a changin'
    James J Ferguson
    Tex Heart Inst J 30:95-6. 2003
  52. ncbi request reprint Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery
    Jan T Christenson
    Department of Cardiovascular Surgery, University Hospital, Geneva, Switzerland
    Ann Thorac Surg 74:1086-90; discussion 1090-1. 2002
    ..Although the efficacy and cost-effectiveness of IABC have been demonstrated, historically higher complication rates have dissuaded some practitioners from using IABC...
  53. ncbi request reprint Assessing risk after acute myocardial infarction
    Gary M Idelchik
    J Am Coll Cardiol 49:2227; author reply 2227-8. 2007
  54. ncbi request reprint Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?
    Elliott M Antman
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:2604-7. 2003